About CytomX Therapeutics, Inc. - Common Stock (CTMX)
CytomX Therapeutics is a biotechnology company focused on developing innovative cancer therapies through its proprietary Probody™ therapeutic technology. This platform is designed to selectively activate antibody-based treatments in the tumor microenvironment, helping to enhance the efficacy and reduce potential side effects of cancer therapies. CytomX is engaged in creating a pipeline of product candidates aiming to address various types of cancer, leveraging its expertise in protein engineering and immuno-oncology to advance treatment options and improve patient outcomes. The company collaborates with pharmaceutical partners to accelerate the development of its therapeutic candidates, with the goal of bringing novel, targeted therapies to market. Read More
The company shared Phase 1 trial results for CX-2051, an antibody-drug conjugate for advanced colorectal cancer, with 28% of patients achieving confirmed partial responses.
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
